Where Cures for Brain Diseases Begin.

Annual Report 2024

Bird's-eye view of a black wooden desk. A research paper rests in the middle of the desk, next to an open laptop, a plastic model of a brain, some pens, and a clipboard with an EEG scan on it.

UNPRECEDENTED PROGRESS

Dear reader, I am thrilled to present the the University of Utah’s Department of Neurology 2024 Highlight Reel.

2024 has been a year of great progress for our department, marked by innovation, collaboration, and growth in clinical care, education, research, and outreach. Together, we’ve continued to enhance our programs and services to meet the evolving needs of the communities we serve. This year, we celebrated many milestones.

Among our accomplishments:

  • New clinical trials launched to explore cutting-edge treatments.
  • Innovative educational programs aimed at training the next generation of neurologists.
  • Expanded community outreach initiatives, fostering greater access to care and education.

These achievements would not be possible without the efforts of our faculty, staff, nurses, and hospital partners. Their commitment to our mission inspires progress every day.

I hope you will feel as energized as we are about the future of the Neurology Department. Thank you for your continued interest and support.

Enjoy!

Waist-up image of Dr. Pulst in a white lab coat, smiling at the camera.

Stefan M. Pulst, MD, Dr med - Chair of the Department of Neurology

Neurology at a glance

Mountain range

We supported

131 Faculty

133 Staff

43Trainees

We opened

The Long-Term Epilepsy Monitoring Unit

We committed

$14M

in Research Funding

We hosted over

48,000

Clinic Visits

Spotlights

AFTER 25 YEARS, RESEARCHERS UNCOVER GENETIC CAUSE OF RARE NEUROLOGICAL DISEASE

This is not just science. This is somebody's life.

- Pattie Figueroa, First Author -

Spinocerebellar ataxia 4 is a severe progressive move-ment disease that can begin as early as the late teens. Now, a multinational research team led by our researchers has uncovered the cause.

Some families call it a trial of faith. Others just call it a curse. The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare condition, but its effects on patients and their families can be severe. For most people, the first sign is difficulty walking and balancing, which gets worse as time progresses. The symptoms usually start in a person’s forties or fifties but can begin as early as the late teens. There is no known cure. And, until now, there was no known cause.

Now, after 25 years of uncertainty, a multinational study led by Stefan Pulst, MD, Dr med, professor and chair of neurology, and K. Pattie Figueroa, a project manager in neurology, both in the Spencer Fox Eccles School of Medicine at University of Utah, has conclusively identified the genetic difference that causes SCA4, bringing answers to families and opening the door to future treatments. Their results are published in the peer-reviewed journal Nature Genetics.

LONG-TERM MONITORING, BETTER EPILEPSY CARE

Our new Long-Term Monitoring Unit is here to help epilepsy patients round-the-clock.

Determining the origins of epilepsy is a tricky business. Sometimes, the cause is genetic; it just runs in the family. Other times, epilepsy is “acquired”—perhaps there was a stroke or head injury, and epilepsy developed as a result. And, according to the National Institute of Neurological Issues and Stroke, about half of people living with epilepsy do not know the cause at all.
Neurological exams, initial imaging tests, blood work, and EEGs (electroencephalograms, which record brain waves) are all used to diagnose epilepsy and monitor seizures.

But many of these methods can be inconclusive, with outpatient EEGs capturing abnormal brain wave activity only about half the time. In contrast, long-term monitoring captures that information in about 80%–85% of patients. This leads to better data for epileptologists, allowing them to develop more tailored treatment plans.

So why doesn’t everyone undergo long-term monitoring? The answers vary. Some respond well to other exams and medications, while others face barriers such as the neurologist shortage in Utah or long wait times.

Our dedicated Long-Term Epilepsy Monitoring Unit was created to fill this critical gap in care. Opened earlier this year in the Neilsen Rehabilitation Center, the unit is staffed 24/7 with experienced technologists and equipped with state-of-the-art monitoring facilities. As the first long-term monitoring unit in the Mountain West, it has always been our mission to provide the highest level of care to our patients. With increased capacity, we are proud to be the largest such facility in the region.

“Having a designated space is life-changing for our patients, our doctors, and us as techs,” said Alise Payne, a supervisor for the unit. “We have these promises that we can fulfill now . . . we’re able to take care of patients in a timely manner. They don’t have to wait for us.”

Having a designated space is life-changing for our patients, Our doctors, and us as techs.
Alise Payne, Supervisor for the Unit

The unit has already made a difference, especially with patients who are having a hard time with medications. During a stay at the unit, patients are safely taken off their medications and closely monitored; with the new data collected, their care team can determine what’s working and what’s not. With the right treatment plan, people with epilepsy can drive again, or even become seizure-free. In some cases, they even wean off medication.

“We want our patients to be independent,” said Payne.

Take the first step toward better epilepsy care today. Whether you’re seeking a diagnosis, exploring treatment options, or simply learning more, our team is here to help. Contact us to learn how the Long-Term Epilepsy Monitoring Unit can support your journey to improved health and peace of mind.

Meet our department

COGNITIVE NEUROLOGY

Division Chief: Paolo Moretti, MD

Cognitive neurology can help you understand the bridge between brain function and behavior.

EPILEPSY

Division Chief: Amir Arain, MD, MPH

Epilepsy, the second-most common neurological disorder after stroke, affects 1 in 26 people, and we’re committed to changing lives with advanced treatments and expert care.

GENERAL NEUROLOGY

Division Chief: Mark Bromberg, MD, PhD

Our division excels in diagnosing and managing complex cases of all types. Our team also works with other divisions, ensuring patients have access to specialized care when needed.

HEADACHE & NEURO-OPHTHALMOLOGY

Division Chief: Susan Baggaley, FNP-BC, MSN

Headache is one of the most common reasons people visit the doctor, affecting 10–20% of individuals with recurring pain. As the only certified headache center in the Mountain West, we offer expert care to help patients manage and overcome headache disorders.

NEUROCRITICAL CARE

Division Chief: Holly Ledyard, MD, MS

Our Neurocritical Care Division is here for you, 24/7. We focus on providing life-saving treatment for patients with severe neurological conditions.

NEUROIMMUNOLOGY & AUTOIMMUNE NEUROLOGY

Division Chief: John Rose, MD

With over 30 years of expertise, the Neuroimmunology and Autoimmune Neurology Division specializes in diagnosing and treating complex immune-mediated inflammatory disorders of the central nervous system (CNS).

NEUROMUSCULAR

Division Chief: Ligia Onofrei, MD

Neuromuscular neurology focuses on diagnosing and treating conditions that affect the nerves, muscles, and the connections between them.

NEUROPSYCHOLOGY

Division Chief: Lindsay Embree, PhD

At the Neuropsychology Division, we help patients across all age groups understand and manage cognitive challenges caused by conditions like brain injuries, dementia, or neurological diseases.

SLEEP & MOVEMENT DISORDERS

Division Chief: Paolo Moretti, MD

We celebrated multiple successes this year. By expanding our team, we’ve reduced patient wait times from nearly two years to just a few weeks. We were also designated as a Multiple System Atrophy (MSA) Center of Excellence and Ataxia Center of Excellence.

VASCULAR NEUROLOGY

Division Chief: Jennifer Majersik, MD, MS

As the region’s first Comprehensive Stroke Center, we provide 24/7, world-class care. Our multidisciplinary team, including neurologists, neurosurgeons, and neurointerventional specialists, ensures the best outcomes for our patients.

RECOGNIZING OUR RESEARCHERS

KC BRENNAN, MD

GRANTS:

  • Sensory Amplifications as Biomarkers of Migraine Progression [R61]
  • Noncanonical Glutamate Signaling in the Origins of the Migraine Attack [R37]

STACEY CLARDY, MD, PHD

GRANT:

  • A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease [U01]

EMILY DENNIS, PHD

GRANTS:

  • Personalized Profiles of Pathology in Pediatric Traumatic Brain Injury [R01]
  • Advancing Secondary Data Analysis: the ENIGMA Brain Injury Data Harmonization Initiative [R33]

JENNIFER JUHL MAJERSIK, MD, MS

GRANTS:

  • UT StrokeNet [U24]
  • Clinical and Translational Science Award UM1 Program at University of Utah [1UM1TR004409]

STEFAN M. PULST, MD, DR MED
Chair of the Department of Neurology

GRANTS:

  • Ataxin-2 Complex Proteins in Neurodegeneration [R35]
  • The Utah Parkinson Disease Registry [Utah Department of Health and Human Services]

DANIEL SCOLES, PHD

GRANTS:

  • PASK-regulated Genes and Proteins as Therapeutic Targets for ALS and FTD [R01]
  • Investigation on Ataxin2 and Matrin3 in Neurodegenerative Disease [R21]
  • Regulation of Paraspeckles by STAU1 in Neurodegenerative Disease [R21]
  • Targeting STAU1 for TDP-43 Proteinopathies [R33]

J. ROBINSON SINGLETON, MD

GRANT:

  • The Utah Regional Network for Excellence in Neuroscience Clinical Trials (UR-NEXT)

Neurologists in action

Neurologists at the University of Utah provide numerous outreach activities for our local Salt Lake City neighborhoods, patients, and providers across the Mountain West region.

CONFERENCES

Epilepsy Symposium
POTS & Beyond
Utah Parkinson’s Disease Symposium
Utah Regional Stroke & Neurorehabilitation
WINO

LOCAL OUTREACH

American Heart Association’s Heart and Stroke Walk
CureSMA Walk-N-Roll
Miles for Migraine
RUUTE & CEE
Walk MS
Walk to End Epilepsy

VIRTUAL OUTREACH

The Dizzy School™
The Headache School™
Talks with Docs
The Utah END Institute

RESEARCH AS ART

While these might look like lesser known Jackson Pollock pieces, these images are actually pictures of cells taken under a microscope.

STAUFEN 1 protein labeled with a red fluorescent marker in the ventral spinal cord of an animal model of neurodegeneration. Credit: Mandi Gandelman, PhD.
Human lab-grown motor neuron labeled with a green fluorescent marker. Credit: Mandi Gandelman, PhD.
STAUFEN 1 protein labeled with a red fluorescent marker in the spinal cord of an animal model of neurodegeneration. Credit: Mandi Gandelman, PhD.
Seizure spreading depolarization after traumatic brain injury. Credit: Translational Neurosciences Laboratory.

UTAH AT AAN

70+

EVENTS

50+

TEAM MEMBERS

30

LEAD PRESENTATIONS

9

LEARNING ENVIRONMENTS

Thank you

As we reflect on key moments from 2024, we look ahead to new challenges, growth, and innovation. Click below for our full annual report, where we'll share even more to celebrate!

Enjoy journeying with us?

Special thanks to J. Steven Price for his generous contribution to the 2024 Annual Report.